<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638673</url>
  </required_header>
  <id_info>
    <org_study_id>00101270</org_study_id>
    <secondary_id>U54GM104941-08</secondary_id>
    <nct_id>NCT04638673</nct_id>
  </id_info>
  <brief_title>NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis</brief_title>
  <official_title>Testing a Wearable Telemedicine-controllable taVNS Device for NeuroCovid Recovery and Rehab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research is to test out a new form of treatment that examines stimulation&#xD;
      of a nerve in the participant's ear. This is called transcutaneous (through the skin)&#xD;
      auricular (ear) vagus nerve stimulation (taVNS) which means that the participant will receive&#xD;
      stimulation through the ear. The taVNS device looks like an ear bud used with a smart phone&#xD;
      or computer. The study team is investigating whether or not taVNS can treat neurologic&#xD;
      symptoms of COVID-19 which are termed NEUROCOVID. Some symptoms the participant may&#xD;
      experience are new onset anxiety, depression, vertigo, loss of smell, headaches, fatigue,&#xD;
      irritability, etc. This study is entirely online and all assessments will be completed&#xD;
      virtually.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Score of Patient Health Questionnaire-9</measure>
    <time_frame>Baseline and week 4 (End of Treatment)</time_frame>
    <description>The Patient Health Questionnaire-9 (PHQ-9) is a 9-question instrument given to patients in a primary care setting to screen for the presence and severity of depression. Scores range from 0-27. Higher scores mean worse symptoms.&#xD;
Remission -minimal to absence of symptoms; PHQ-9 score &lt; 5. Response -50% or greater decrease in PHQ-9 baseline severity; residual symptoms remain. Partial Response -26% to 49% decrease in PHQ-9 baseline severity. Non-response -less than 25% decrease in PHQ-9 baseline severity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Coronavirus</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Active-Active Stimulation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be randomized into the active stimulation group for weeks 1&amp;2 of stimulation and active stimulation during weeks 3&amp;4 of stimulation of study participation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham-Active Stimulation Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will be randomized into the sham stimulation group for weeks 1&amp;2 of stimulation and active stimulation for weeks 3&amp;4 of stimulation of study participation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Soterix taVNS model 0125-LTE Stimulator - Active-Active Group</intervention_name>
    <description>Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.</description>
    <arm_group_label>Active-Active Stimulation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group</intervention_name>
    <description>Participants will receive sham taVNS stimulation for weeks 1&amp;2 and active stimulation for weeks 3&amp;4 of the stimulation portion of this study.</description>
    <arm_group_label>Sham-Active Stimulation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COVID positive&#xD;
&#xD;
          -  At home&#xD;
&#xD;
          -  Afebrile&#xD;
&#xD;
          -  Anxiety&#xD;
&#xD;
          -  Depression&#xD;
&#xD;
          -  Vertigo&#xD;
&#xD;
          -  Anosmia&#xD;
&#xD;
          -  Headaches&#xD;
&#xD;
          -  Irritability&#xD;
&#xD;
          -  Cognitive Processing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Damage to left ear anatomy&#xD;
&#xD;
          -  Unstable hemodynamic effects&#xD;
&#xD;
          -  Ischemic or hemorrhagic stroke after developing COVID&#xD;
&#xD;
          -  Unable to give consent, follow instructions&#xD;
&#xD;
          -  Unable to read or write or speak English&#xD;
&#xD;
          -  No access to home WiFi&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark S George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>November 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <results_first_submitted>June 20, 2022</results_first_submitted>
  <results_first_submitted_qc>July 25, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2022</results_first_posted>
  <last_update_submitted>July 25, 2022</last_update_submitted>
  <last_update_submitted_qc>July 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Mark S. George , MD</investigator_full_name>
    <investigator_title>Distinguished University Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT04638673/Prot_SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 22, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT04638673/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One participant was removed after consent for failure to satisfy all inclusion requirements.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Active-Active Stimulation Group</title>
          <description>This group will be randomized into the active stimulation group for weeks 1&amp;2 of stimulation and active stimulation during weeks 3&amp;4 of stimulation of study participation.&#xD;
Soterix taVNS model 0125-LTE Stimulator - Active-Active Group: Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.</description>
        </group>
        <group group_id="P2">
          <title>Sham-Active Stimulation Group</title>
          <description>This group will be randomized into the sham stimulation group for weeks 1&amp;2 of stimulation and active stimulation for weeks 3&amp;4 of stimulation of study participation.&#xD;
Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group: Participants will receive sham taVNS stimulation for weeks 1&amp;2 and active stimulation for weeks 3&amp;4 of the stimulation portion of this study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active-Active Stimulation Group</title>
          <description>This group will be randomized into the active stimulation group for weeks 1&amp;2 of stimulation and active stimulation during weeks 3&amp;4 of stimulation of study participation.&#xD;
Soterix taVNS model 0125-LTE Stimulator - Active-Active Group: Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.</description>
        </group>
        <group group_id="B2">
          <title>Sham-Active Stimulation Group</title>
          <description>This group will be randomized into the sham stimulation group for weeks 1&amp;2 of stimulation and active stimulation for weeks 3&amp;4 of stimulation of study participation.&#xD;
Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group: Participants will receive sham taVNS stimulation for weeks 1&amp;2 and active stimulation for weeks 3&amp;4 of the stimulation portion of this study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="10.2"/>
                    <measurement group_id="B2" value="46.2" spread="12.0"/>
                    <measurement group_id="B3" value="48.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Score of Patient Health Questionnaire-9</title>
        <description>The Patient Health Questionnaire-9 (PHQ-9) is a 9-question instrument given to patients in a primary care setting to screen for the presence and severity of depression. Scores range from 0-27. Higher scores mean worse symptoms.&#xD;
Remission -minimal to absence of symptoms; PHQ-9 score &lt; 5. Response -50% or greater decrease in PHQ-9 baseline severity; residual symptoms remain. Partial Response -26% to 49% decrease in PHQ-9 baseline severity. Non-response -less than 25% decrease in PHQ-9 baseline severity.</description>
        <time_frame>Baseline and week 4 (End of Treatment)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active-Active Stimulation Group</title>
            <description>This group will be randomized into the active stimulation group for weeks 1&amp;2 of stimulation and active stimulation during weeks 3&amp;4 of stimulation of study participation.&#xD;
Soterix taVNS model 0125-LTE Stimulator - Active-Active Group: Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.</description>
          </group>
          <group group_id="O2">
            <title>Sham-Active Stimulation Group</title>
            <description>This group will be randomized into the sham stimulation group for weeks 1&amp;2 of stimulation and active stimulation for weeks 3&amp;4 of stimulation of study participation.&#xD;
Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group: Participants will receive sham taVNS stimulation for weeks 1&amp;2 and active stimulation for weeks 3&amp;4 of the stimulation portion of this study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score of Patient Health Questionnaire-9</title>
          <description>The Patient Health Questionnaire-9 (PHQ-9) is a 9-question instrument given to patients in a primary care setting to screen for the presence and severity of depression. Scores range from 0-27. Higher scores mean worse symptoms.&#xD;
Remission -minimal to absence of symptoms; PHQ-9 score &lt; 5. Response -50% or greater decrease in PHQ-9 baseline severity; residual symptoms remain. Partial Response -26% to 49% decrease in PHQ-9 baseline severity. Non-response -less than 25% decrease in PHQ-9 baseline severity.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="6.3"/>
                    <measurement group_id="O2" value="-5.5" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks (duration of taVNS stimulation period)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active-Active Stimulation Group</title>
          <description>This group will be randomized into the active stimulation group for weeks 1&amp;2 of stimulation and active stimulation during weeks 3&amp;4 of stimulation of study participation.&#xD;
Soterix taVNS model 0125-LTE Stimulator - Active-Active Group: Participants will receive active taVNS stimulation for weeks 1-4 of the stimulation portion of this study.</description>
        </group>
        <group group_id="E2">
          <title>Sham-Active Stimulation Group</title>
          <description>This group will be randomized into the sham stimulation group for weeks 1&amp;2 of stimulation and active stimulation for weeks 3&amp;4 of stimulation of study participation.&#xD;
Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group: Participants will receive sham taVNS stimulation for weeks 1&amp;2 and active stimulation for weeks 3&amp;4 of the stimulation portion of this study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation/Redness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark S. George</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-876-5142</phone>
      <email>georgem@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

